Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 1057-1063

  Nakamura, Akiko ^a   Furuta, Takahisa ^a   Shirai, Naohito ^a   Sugimoto, Mitsushige ^a   Kajimura, Masayoshi ^a   Soya, Yoshihiro ^b   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Biotechnology Frontier Project   (Japan)

Author keywords

23S rRNA; Allele specific primer polymerase chain reaction; Clarithromycin; Helicobacter pylori; Single nucleotide polymorphism

Indexed keywords

ADENINE; BACTERIAL RNA; CLARITHROMYCIN; DNA; GUANINE; RNA 23S; UREASE;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; CONTROLLED STUDY; DNA EXTRACTION; DRUG TREATMENT FAILURE; FEMALE; FUNCTION TEST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH; UREA BREATH TEST; WILD TYPE;

EID: 34347398534     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04546.x     Document Type: Article

References (38)

1. Wotherspoon AC. Helicobacter pylori infection and gastric lymphoma. Br. Med. Bull. 1998 54 : 79 85.
2. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997 41 : 8 13.
3. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001 345 : 784 9.
4. Marshall BJ, Goodwin CS, Warren JR et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988 2 : 1437 42.
5. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice parameters committee of the American College of Gastroenterology. JAMA 1996 275 : 622 9.
6. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann. Intern. Med. 1997 126 : 280 91.
7. Mukai M, Kon Y, Notoya A, Kohno M. Helicobacter pylori associated with idiopathic thrombocytopenic purpura. Am. J. Med. 2002 113 : 169 71.
8. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 1995 333 : 984 91.
9. Perri F, Qasim A, Marras L, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2003 8 (Suppl. 1 53 60.
10. Unge P. Review of Helicobacter pylori eradication regimens. Scand. J. Gastroenterol. Suppl. 1996 215 : 74 81.
11. Lind T, Megraud F, Unge P et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999 116 : 248 53.
12. Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001 69 : 158 68.
13. Murakami K, Sato R, Okimoto T et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 2002 16 : 1933 8.
14. Maeda S, Yoshida H, Matsunaga H et al. Detection of clarithromycin- resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J. Clin. Microbiol. 2000 38 : 210 14.
15. Kawabata H, Habu Y, Tomioka H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 2003 17 : 259 64.
16. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol. 2002 51 : 705 9.
17. Vega AE, Alarcon T, Domingo D, Martinez MJ, Lopez-Brea M. [Detection of resistance to clarithromycin in clinical isolates of Helicobacter pylori from children and adults]. Rev. Esp. Quimioter. 2003 16 : 53 7 (in Spanish with an English abstract).
18. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004 53 : 1374 84.
19. Booka M, Okuda M, Shin K et al. Polymerase chain reaction - restriction fragment length polymorphism analysis of clarithromycin-resistant Helicobacter pylori infection in children using stool sample. Helicobacter 2005 10 : 205 13.
20. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents Chemother. 1995 39 : 2625 30.
21. Menard A, Santos A, Megraud F, Oleastro M. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob. Agents Chemother. 2002 46 : 1156 7.
22. Stone GG, Shortridge D, Versalovic J et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agents Chemother. 1997 41 : 712 14.
23. Fontana C, Favaro M, Minelli S et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob. Agents Chemother. 2002 46 : 3765 9.
24. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 1997 41 : 2621 8.
25. Ishiguro A, Kubota T, Soya Y et al. High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction. Anal. Biochem. 2005 337 : 256 61.
26. Dent JC, McNulty CA. Evaluation of a new selective medium for Campylobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 1988 7 : 555 8.
27. Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S. Sensitive detection of Helicobacter pylori by using polymerase chain reaction. J. Clin. Microbiol. 1992 30 : 192 200.
28. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am. J. Gastroenterol. 1998 93 : 386 9.
29. Furuta T, Shirai N, Xiao F et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin. Gastroenterol. Hepatol. 2004 2 : 22 30.
30. Furuta T, Shirai N, Ohashi K, Ishizaki T. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find. Exp. Clin. Pharmacol. 2003 25 : 131 43.
31. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004 5 : 181 202.
32. Take S, Mizuno M, Ishiki K et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 2003 98 : 2403 8.
33. Labenz J, Stolte M, Blum AL et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995 37 : 39 43.
34. Kamada T, Haruma K, Komoto K et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999 4 : 204 10.
35. Hulten K, Gibreel A, Skold O, Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob. Agents Chemother. 1997 41 : 2550 3.
36. Sevin E, Lamarque D, Delchier JC, Soussy CJ, Tankovic J. Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR. FEMS Microbiol. Lett. 1998 165 : 369 72.
37. Umegaki N, Shimoyama T, Nishiya D, Suto T, Fukuda S, Munakata A. Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Japan. J. Gastroenterol. Hepatol. 2000 15 : 906 9.
38. Yang YJ, Yang JC, Jeng YM, Chang MH, Ni YH. Prevalence and rapid identification of clarithromycin-resistant Helicobacter pylori isolates in children. Pediatr. Infect. Dis. J. 2001 20 : 662 6.